{"id":"sctc21c","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CAR-T cell therapies involve genetically modifying a patient's own T cells to express chimeric antigen receptors that recognize tumor-specific antigens, enabling enhanced recognition and killing of malignant cells. SCTC21C is designed to redirect T-cell specificity toward cancer cells while minimizing off-target effects. This approach leverages the patient's immune system for durable anti-tumor activity.","oneSentence":"SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:33:47.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hematologic malignancies (specific indication under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT07388602","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2026-01-08","conditions":"Amyloidosis","enrollment":90},{"nctId":"NCT07297329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-12-29","conditions":"Multiple Myeloma (MM)","enrollment":292},{"nctId":"NCT06774664","phase":"PHASE1, PHASE2","title":"A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-01","conditions":"IgA Nephropathy","enrollment":99},{"nctId":"NCT06252298","phase":"PHASE1","title":"A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2024-02-28","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SCTC21C","genericName":"SCTC21C","companyName":"Sinocelltech Ltd.","companyId":"sinocelltech-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"SCTC21C is a chimeric antigen receptor T-cell (CAR-T) therapy engineered to target and eliminate cancer cells expressing specific tumor-associated antigens. Used for Hematologic malignancies (specific indication under investigation in phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}